Genomoncology Expands Board Of Directors With New Appointment Of Jeff Shine

Shiner has over two decades of expertise directing rapid company development and innovation, which will be critical to GenomOncology's future.

Fremont, CA: GenomOncology, a premier precision oncology software development firm, appointed Jeff Shiner, CEO of 1Password, to its Board of Directors. Shiner has over two decades of expertise directing rapid company development and innovation, which will be critical to GenomOncology's future.

"We are thrilled that Jeff is joining the GenomOncology Board of Directors. As the industry continues to mature, we are excited about the opportunity to expand the reach of our precision oncology solutions to new and innovative markets," said Brad Wertz, Chief Executive Officer at GenomOncology. "He has a demonstrated history of growing businesses and pushing the boundaries when it comes to innovating in tech, which will be crucial for our future. Jeff has been very involved with GenomOncology for some time and I expect this appointment to increase his involvement and impact moving forward."